Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08), Zacks reports.
Vigil Neuroscience Price Performance
NASDAQ:VIGL opened at $2.16 on Thursday. The firm's fifty day moving average price is $2.33 and its 200 day moving average price is $2.81. Vigil Neuroscience has a 1-year low of $1.49 and a 1-year high of $6.06. The firm has a market cap of $88.30 million, a price-to-earnings ratio of -1.04 and a beta of 1.82.
Analyst Upgrades and Downgrades
VIGL has been the topic of a number of recent analyst reports. JMP Securities restated a "market outperform" rating and set a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. William Blair initiated coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $17.00 target price on shares of Vigil Neuroscience in a research report on Thursday, January 23rd. Finally, Guggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $19.75.
Check Out Our Latest Research Report on Vigil Neuroscience
Vigil Neuroscience Company Profile
(
Get Free Report)
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vigil Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.
While Vigil Neuroscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
